Drug Safety news from FierceHealthcare
News
FDA may get $275 million more for staff, outsourcing
Studies show problems with four big-name drugs
ALSO NOTED: WellPoint exposes patient data; ED visits go up when OR trims Medicaid rolls; and much more...
Study: Errors caused 200K+ deaths from '04 to '06
ALSO NOTED: TN Medicaid to test e-prescribing program; NIH alerts patients of stolen personal information; and much more...
Congress poised to give more power to the FDA
Study: Physicians dismiss complaints about statins
SPOTLIGHT: Outsiders should see FDA safety data
Some say that if outside researchers had access to drug safety data, disasters like the Vioxx scandal might have been avoided. At present, however, the FDA doesn't let outsiders see clinical trial data unless forced to do so. This secrecy can only do harm, suggests a new commentary in Health Affairs. Report
Physicians, hospitals not thrilled by FDA proposals
With physicians and hospitals offering only lukewarm support to proposed FDA reforms of its drug safety policy and communications with the public and providers, Congress is likely to push ahead with plans of its own to regulate the agency, experts say. Physician groups like the AMA and Medical Group Management Association said they were pleased with the FDA's plans to notify physicians more quickly about drug safety concerns, though as MGMA president noted, the FDA still has little …
Read more...Cerner to acquire Galt & Associates
This is another noteworthy deal for Cerner, which as been the subject of rumors involving the massive NHS IT project in the U.K. The Kansas City-based maker of healthcare software appears to be making good on Neal Patterson's pledge to expand into new territory with the acquisition of Galt & Associates, a maker of drug safety and clinical data management systems. The Fairfax, VA-based company has 10 employees and recorded $9.5 million in revenue last year.
- see this article from the Business Journal of Kansas City
Get more Drug Safety coverage at:
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies




